DAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive: To the best of our knowledge, however, no study has been conducted investigating the correlation between the presence of methylation in the DAPK1 promoter region and mutations that confer resistance to imatinib therapy in CML patients.